The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Abstract
Summary: Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders. Dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for routine coagulation monitoring. In certain clinical situations such as serious bleeding into critical organs (e.g. intracerebral bleeding), potential overdose and emergency surgery, clinicians will need to make an assessment of the anticoagulant status of a patient receiving dabigatran before deciding on future management strategies. If available, thrombin clotting time (TT), ecarin clotting time (ECT) and TT determined by Hemoclot→ thrombin inhibitor assay are sensitive tests to evaluate the anticoagulant effects of dabigatran. Prothrombin time (INR) is less sensitive than other assays and cannot be recommended. The activated partial thromboplastin time (aPTT) can provide a useful qualitative assessment of anticoagulant activity but is less sensitive at supratherapeutic dabigatran levels. There are limited data for activated clotting time (ACT). Overall, the aPTT and TT are the most accessible qualitative methods for determining the presence or absence of anticoagulant effect. Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity. In case of potential overdose, the feasibility of early administration of activated charcoal and subsequent charcoal filtration are undergoing preclinical evaluation. Dabigatran can also be dialysed in patients with renal impairment. In instances of life-threatening bleeding, where conventional measures have failed or are unavailable, other non-specific prohaemo -static agents such as recombinant activated factor VII and prothrombin complex concentrates can be considered. Disclosure statement: All authors are employees of Boehringer Ingelheim. Figure 1 has been corrected in this version of the article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A. A., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.612812 · Cited by 1,341
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Self-citationManoukian, S. V., Feit, F., Mehran, R., Voeltz, M. D., Ebrahimi, R., Hamon, M., Dangas, G. D., Lincoff, A. M., White, H. D., Moses, J. W., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.027 · Cited by 798
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
Self-citationThe Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Self-citationStangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Self-citationImpact of Bleeding Severity on Clinical Outcomes Among Patients With Acute Coronary Syndromes
Rao, S. V., O’Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K., Van de Werf, F., Mahaffey, K. W., Califf, R. M., & Harrington, R. A. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.056 · Cited by 631
Platelet activity of high‐dose factor VIIa is independent of tissue factor
Monroe, D. M., Hoffman, M., Oliver, J. A., & Roberts, H. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4463256.x · Cited by 534
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
Hauel, N. H., Nar, H., Priepke, H., Ries, U., Stassen, J.-M., & Wienen, W. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0109513 · Cited by 457
Self-citationStangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Self-citationEzekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Self-citationLeissinger, C. A., Blatt, P. M., Hoots, W. K., & Ewenstein, B. (2008) · American Journal of Hematology · doi:10.1002/ajh.21046 · Cited by 353
Crowther, M. A., & Warkentin, T. E. (2008) · Blood · doi:10.1182/blood-2007-10-120543 · Cited by 314
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Self-citationStassen, J.-M., Priepke, H., Ries, U. J., Hauel, N., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250
Self-citationLubetsky, A., Yonath, H., Olchovsky, D., Loebstein, R., Halkin, H., & Ezra, D. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2469 · Cited by 227
Anticoagulants and Their Reversal
Schulman, S., & Bijsterveld, N. R. (2007) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2006.08.002 · Cited by 212
Combining Antiplatelet and Anticoagulant Therapies
Holmes, D. R., Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., & Grines, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.044 · Cited by 155
The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors
Nowak, G. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000081505 · Cited by 146
Liesenfeld, K., Schäfer, H. G., Trocóniz, I. F., Tillmann, C., Eriksson, B. I., & Stangier, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02667.x · Cited by 118
Self-citationNunnelee, J. D. (2010) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2010.03.002 · Cited by 111
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
Crowther, M. A., & Warkentin, T. E. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03429.x · Cited by 98
Porsche, R., & Brenner, Z. R. (1999) · Heart & Lung · doi:10.1016/s0147-9563(99)70031-2 · Cited by 93
Stratmann, G., DeSilva, A., Tseng, E. E., Hambleton, J., Balea, M. C., Romo, A. J., Mann, M. J., Achorn, N., Moskalik, W., & Hoopes, C. W. (2004) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000114072.71353.d5 · Cited by 76
Oh, J. J., Akers, W. S., Lewis, D. A., et al. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.4.576 · Cited by 54
Sartori, M. T., Imbergamo, S., Zanon, E., Bonaccorso, G., Pittoni, G. M., Feltracco, P., Ori, C., Pagnan, A., & Cella, G. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609335909 · Cited by 18
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Self-citationAgeno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Metadata
- Authors
- Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2010
- Volume
- 103
- Issue
- 06
- Pages
- 1116-1127
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2113446992
- Cited by
- 1,382
- References
- 31
- FWCI
- 151.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.